Therapeutic Responses to AZT 1 3TC 1 EFV in Advanced Antiretroviral Naive HIV Type 1-Infected Ugandan Patients

dc.contributor.authorKebba, Anthony
dc.contributor.authorAtwine, Diana
dc.contributor.authorMwebaze, Raymond
dc.contributor.authorKityo, Cissy
dc.contributor.authorNakityo, Rose
dc.contributor.authorMulenyi, Peter
dc.date.accessioned2021-04-21T13:10:40Z
dc.date.available2021-04-21T13:10:40Z
dc.date.issued2004-07-05
dc.description.abstractConvenient, non-food-dependent dosing, low tablet volume, and relatively low cost have made nonnucleoside reverse transcriptase inhibitors a first choice for both clinicians and patients in Uganda. Concerns exist as to their efficacy in patients with viral loads (VL) above 100,000 copies/ml, a feature common to about 75% of HIV-1-infected patients presenting at the Joint Clinical Research Center (JCRC) in Uganda. Furthermore, there are few data on the response to such therapy of non-B subtypes, A and D, predominant in Uganda. Presented here is a retrospective analysis of therapeutic responses in 11 antiretroviral (ARV) naïve HIV-1-infected Ugandan patients who had been initiated on zidovudine (AZT), lamivudine (3TC), and efavirenz (EFV). Laboratory assessments subsequent to initiation of ARV therapy, done at 11.6 ± 3.9 weeks and 30.6 ± 5.9 weeks, showed 88.9 and 71.4% patients achieved undetectable viral load, respectively. Virological suppression to below detection occurred in 85.7% of patients at 11.6 weeks despite baseline VL ≥ 100,000 copies/ml. At 31 weeks there was a median increment of +183 cells/mm3 in CD4+ T lymphocytes. These findings reflect significant efficacy in the use of AZT + 3TC + EFV in advanced ARV naive non-B subtype HIV-1-infected patients. The therapeutic responses were comparable to those previously described in the western world.en_US
dc.identifier.citationKebba, A., Atwine, D., Mwebaze, R., Kityo, C., Nakityo, R. and Peter, M., 2002. Therapeutic responses to AZT+ 3TC+ EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients. AIDS research and human retroviruses, 18(16), pp.1181-1187.en_US
dc.identifier.issn0889-2229
dc.identifier.issn1931-8405
dc.identifier.urihttp://hdl.handle.net/20.500.12280/2680
dc.language.isoenen_US
dc.publisherMary Ann Liebert, Inc.en_US
dc.relation.ispartofseriesAIDS Research and Human Retroviruses;18(16)
dc.subjectTherapeutic responsesen_US
dc.subjectPatientsen_US
dc.subjectAntiretroviralen_US
dc.subjectNaive HIV type 1en_US
dc.subjectUgandaen_US
dc.titleTherapeutic Responses to AZT 1 3TC 1 EFV in Advanced Antiretroviral Naive HIV Type 1-Infected Ugandan Patientsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Mwebaze_ARTICLE_MKPGS_2002_Therapautic.pdf
Size:
416.71 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: